AbbVie: Rinvoq available in U.S. for patients two and older with pJIA, PsA

AbbVie announced that Rinvoq is indicated in the U.S. for the treatment of pediatric patients two years of age and older with active polyarticular juvenile idiopathic arthritis as well as psoriatic arthritis, provided they have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. Additionally, a new weight-based oral solution, Rinvoq LQ, is now available as an option for these pediatric populations.